121 related articles for article (PubMed ID: 30904441)
1. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.
Del Rio-Moreno M; Alors-Perez E; Borges de Souza P; Prados-Gonzalez ME; CastaÑo JP; Luque RM; Gahete MD
Transl Res; 2019 Sep; 211():147-160. PubMed ID: 30904441
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor Splicing Variant
Fuentes-Fayos AC; G-García ME; Pérez-Gómez JM; Peel A; Blanco-Acevedo C; Solivera J; Ibáñez-Costa A; Gahete MD; Castaño JP; Luque RM
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163067
[TBL] [Abstract][Full Text] [Related]
3. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
[TBL] [Abstract][Full Text] [Related]
4. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP
Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030
[TBL] [Abstract][Full Text] [Related]
5. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
6. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients.
Gahete MD; Rincón-Fernández D; Durán-Prado M; Hergueta-Redondo M; Ibáñez-Costa A; Rojo-Sebastián A; Gracia-Navarro F; Culler MD; Casanovas O; Moreno-Bueno G; Luque RM; Castaño JP
Oncotarget; 2016 Sep; 7(37):60110-60122. PubMed ID: 27507050
[TBL] [Abstract][Full Text] [Related]
7. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
8. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.
Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC
Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors.
Durán-Prado M; Gahete MD; Martínez-Fuentes AJ; Luque RM; Quintero A; Webb SM; Benito-López P; Leal A; Schulz S; Gracia-Navarro F; Malagón MM; Castaño JP
J Clin Endocrinol Metab; 2009 Jul; 94(7):2634-43. PubMed ID: 19401364
[TBL] [Abstract][Full Text] [Related]
10. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
[TBL] [Abstract][Full Text] [Related]
12. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer.
Puig-Domingo M; Luque RM; Reverter JL; López-Sánchez LM; Gahete MD; Culler MD; Díaz-Soto G; Lomeña F; Squarcia M; Mate JL; Mora M; Fernández-Cruz L; Vidal O; Alastrué A; Balibrea J; Halperin I; Mauricio D; Castaño JP
PLoS One; 2014; 9(1):e85527. PubMed ID: 24465589
[TBL] [Abstract][Full Text] [Related]
13. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
14. Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line.
Cambiaghi V; Vitali E; Morone D; Peverelli E; Spada A; Mantovani G; Lania AG
Endocrine; 2017 Apr; 56(1):146-157. PubMed ID: 27406390
[TBL] [Abstract][Full Text] [Related]
15. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
16. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs.
Buchsbaum DJ
Semin Nucl Med; 2004 Jan; 34(1):32-46. PubMed ID: 14735457
[TBL] [Abstract][Full Text] [Related]
17. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity.
Taylor JE; Theveniau MA; Bashirzadeh R; Reisine T; Eden PA
Peptides; 1994; 15(7):1229-36. PubMed ID: 7854974
[TBL] [Abstract][Full Text] [Related]
18. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
Pedraza-Arévalo S; Hormaechea-Agulla D; Gómez-Gómez E; Requena MJ; Selth LA; Gahete MD; Castaño JP; Luque RM
Prostate; 2017 Nov; 77(15):1499-1511. PubMed ID: 28905400
[TBL] [Abstract][Full Text] [Related]
20. Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth.
Ruscica M; Magni P; Steffani L; Gatto F; Albertelli M; Rametta R; Valenti L; Ameri P; Magnaghi V; Culler MD; Minuto F; Ferone D; Arvigo M
Mol Cell Endocrinol; 2014 Feb; 382(2):860-70. PubMed ID: 24211300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
